News archive
Showing 696 results
April 2012
-
Media Release
Novartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
-
Media Release
Novartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
Now available in US pharmacies, Hecoria (tacrolimus) capsules are approved for the prevention of organ rejection in certain kidney and liver transplant patientsHecoria, a branded generic, complements… -
Media Release
Novartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
March 2012
-
Media Release
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
- Arcapta Neohaler is the only once-daily, 24-hour long-acting beta2-agonist approved for maintenance treatment of airflow obstruction in COPD patients- Arcapta Neohaler showed significant… -
Media Release
Novartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
January 2012
-
Media Release
Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
- Company to resolve wage and hour claims with one-time payment of up to 99 million dollars for eligible class members- Novartis Pharmaceuticals Corporation remains committed to compensate all… -
Media Release
Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
December 2011
-
Media Release
Novartis Pivotal Study of Exjade® Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia
- Trial shows Exjade, an iron chelator, is significantly better than placebo at reducing liver iron concentration in patients with NTDT- Non-transfusion-dependent thalassemia (NTDT) is a genetic… -
Media Release
Novartis Pivotal Study of Exjade® Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia
-
Media Release
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
- ENESTcmr data show 23% of patients switched to Tasigna achieved undetectable levels of Bcr-Abl within 12 months compared to 11% who continued on Gleevec(1)- Three-year ENESTnd data show 32% of… -
Media Release
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®